Day 1 :
Keynote Forum
Alain L Fymat
International Institute of Medicine & Science, USA
Keynote: Nanotechnology may provide new hope for brain cancer therapy
Time : 09:00-09:35
Biography:
Abstract:
Cancer cells are notoriously resistant to drugs intended to kill them by rerouting the signaling networks responsible for cancer cells' growth, proliferation, and survival. A drug may block a particular signaling pathway but within a matter of days (minutes in some cases), cancer cells begin to rely on alternate pathways to promote their survival. The simultaneous use of several drugs (“rational combination therapy”) is meant to attack both the primary and alternate pathways to preemptively block the cancer cells' escape route. Unfortunately, the efficacy of many combination therapies has been limited because drugs have very different chemical properties, which cause them to travel to different parts of the body and enter cancer cells at different rates. The situation is considerably more complicated for brain cancer (glioblastoma multiform or octopus tumor) because the cancer cells extend their tendrils into the surrounding tissue, which is virtually inoperable, resistant to therapies, and always fatal. A major obstacle to treatment is the blood-brain barrier or network of blood vessels that allows essential nutrients to enter the brain but block the passage of other substances. I will describe novel nanotechnology approaches for delivering drugs across and around the brain protective barriers.
Keynote Forum
Raymond C Jagessar
University of Guyana, Guyana
Keynote: Synthesis of porphyrins bearing trans-thiols: A good perspective in nanotechnology
Time : 09:35-10:10
Biography:
Raymond C. Jagessar obtained his BSc (Distinction) in Chemistry/Biology from the University of Guyana (1992) and his Ph.D. from the UK (1995). He held three Post-Doctoral Research Fellowships (PDF) at various universities overseas. He has also won several international awards, amongst them are Chartered Chemist, CChem and Fellow of the Royal Society of Chemistry, FRSC, UK, Research and traveling Grants etc. His research interests are broad, covering the spectrum of Pure and Applied Chemistry, Chemical Biology and Pharmaceutical Chemistry. He has published over eighty (80) research articles, five book chapters and presented at conferences: locally and internationally. He is currently Professor in Chemistry at the University of Guyana (South America).
Abstract:
There are several interesting reports on the electrical properties of meso-substituted porphyrins. Meso-substituted porphyrins electrical properties can be modulated through various meso-substituted patterns and the use of the type of metal in porphyrin metal complexation. This class of compounds has yielded interesting results in the nanopore arena or embodiment. Thus, their availability via high yielding synthesis is necessary. Hence, a route to porphyrins bearing trans-thiols is described in this lecture. The synthesis involves a thioacetyl containing aldehyde or a thioacetyl containing dipyrromethane in the presence of catalytic BF3.OEt2 followed by oxidation. Metal complexation and ammonium hydroxide induced acetyl removal to provide a route to these important molecular systems for future electronics experiments in which the thiols would serve as the adhesion points to gold probes
Keynote Forum
Thomas J Webster
Northeastern University, USA
Keynote: Nanomedicine: Where have we been and where are we going?
Time : 10:10-10:45
Biography:
Thomas J. Webster’s (H index: 84) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995) and in biomedical engineering from RPI (M.S., 1997; Ph.D., 2000). He is the current director of the Nanomedicine Laboratories (currently at 39 members), has graduated/supervised over 149 visiting faculty, fellows, post-doctoral, and thesis completing students. He is the founding editor-in-chief of the International Journal of Nanomedicine (impact factor of 5.03) and directs or co-directs 3 international centers. He is a fellow of numerous societies, former President of the U.S. Society For Biomaterials, and has started 11 companies with 4 FDA products. He has appeared regularly on NBC, CNN, Fox News, and other outlets talking about science and medicine.
Abstract:
There is an acute shortage of organs due to disease, trauma, congenital defects, and most importantly, age-related maladies. The synthetic materials used in tissue engineering applications today are typically composed of a millimeter or micron-sized particles and/or fiber dimensions. Although human cells are on the micron scale, their individual components, e.g. proteins, are composed of nanometer features. By modifying only the nanofeatures on material surfaces without changing surface chemistry, it is possible to increase tissue growth of any human tissue by controlling the endogenous adsorption of adhesive proteins onto the material surface. In addition, our group has shown that these same nanofeatures and nano-modifications can reduce bacterial growth without using antibiotics, which may further accelerate the growth of antibiotic-resistant microbes. Inflammation can also be decreased through the use of nanomaterials. Finally, nanomedicine has been shown to stimulate the growth and differentiation of stem cells, which may someday be used to treat incurable disorders, such as neural damage. This strategy also accelerates FDA approval and commercialization efforts since new chemistries are not proposed, rather chemistries already approved by the FDA with altered nanoscale features. This invited talk will highlight some of the advancements and emphasize current nanomaterials approved by the FDA for human implantation and discuss the future role of implantable sensors in preventing, diagnosing, and treating disease.
Keynote Forum
Oara Neumann
Rice University, USA
Keynote: Plasmonic nanostructures for imaging and targeting drug delivery
Time : 11:00-11:35
Biography:
Oara Neumann is the Peter M. and Ruth L. Nicholas Research Scientist at Rice University. She has completed her Ph.D. and Postdoctoral study in Applied Physics at Rice University, an MSc. in Chemical Physics from Weizmann Institute of Science, Israel, and an MSc. in Analytical Chemistry from Bucharest University, Romania. She is the pioneer of nanoparticle-based solar thermal applications. She holds several patents and she has published more than 24 refereed articles and has an h-index of 16.
Abstract:
Engineering a compact, near-infrared plasmonic nanostructure with integrated image-enhancing agents for combined imaging and therapy is an important nanomedical challenge. To overcome this challenge we designed a nanostructure with NIR plasmonic signatures composed of a 50nm Au core surrounded a SiO2 inner-shell doped with contrast agents and an outer Au shell. The plasmon resonance of this nanostructure, known as a nanomatryoshka (NM), can be tuned to the desired wavelength by varying the thickness of the layers. The encapsulated contrast agents used in this study are: Fe(III)-DOTA, Gd(III)-DOTA, and fluorescent dyes. The Fe(III)-NM based contrast agents are found to have relaxivities two times greater than the widely used Gd(III)-DOTA, providing a practical alternative for T1 MRI contrast agent that eliminates Gd(III) patient exposure entirely. Additionally, the internalization of fluorescent dyes and MRI contrast imaging agents within the NM substantially reduces the toxicity while maintaining a free nanoparticles surface for further bio-functionalization.
Keynote Forum
Arend L Mapanawang
Stikes Halmahera, Indonesia
Keynote: Herbal marine from Laor (Polychaeta) omega complete (omega 3,6,9) as a health supplement
Time : 11:35-12:10
Biography:
Arend L Mapanawang has completed his Ph.D. from the Department of Pharmacy, College of Health Sciences, Yayasan Medika Mandiri Foundation, Halmahera, Indonesia. He is the Director of College of Health Sciences (STIKES Halmahera), Medika Mandiri Foundation, Halmahera, Indonesia. He is the Head of Internal Medicine Departement of Bethesda Hospital in Tobelo North Halmahera, North Moluccas.
Abstract:
Sea worms or Laor (Polychaeta) have important benefits as feed shrimp and fish livestock as well as human health supplements where the ingredients which are very rich in various vitamins, proteins that are quite complete and have the uniqueness because it contains 3 omega (omega 3,6,9) in 1 Polychaeta material, this compound is very good for health supplements both for pregnant women, lactating mothers as well as good for heart health and brain. Prevention of atherosclerosis is very good as it has especially omega compounds. With GC-MS test (Gas Chromatography-Mass), found various components such as Lauric acid 0.130%, Palmitic acid 25.645%, Palmitic acid 2.148%, ARA 0.481%, EPA 3.866%, DHA 2.458%, medium chain 5.560%, Saturated 40,316%, monoenes 18,968%, Lauric acid 12,89%, behenic acid 0,654%, Cis- 8,11,14-cicosa-trienoic 9,956%, CIs-11,14 eicosadienoic 4,056%, Linolenic 14,017%, Oleic acid 11,655%, nervonic acid 1,299%, fig tree 0,481%, N-6 29,861%, N-3 5,294%, Mg 2.132%, mg/ml 21.321%. MTT anti-cancer test 1750μg/ml, FTIR analysis has peak 3738 high, intensity 32, area 28.74, Base (H) 3782, 57, Base (L) 3722,77. With the omega complete (omega 3,6,9,), also EPA, DHA, then very useful for brain nutrition, child intelligence, nutrition of breastfeeding mothers, heart health and brain and health generally other than as a nutritional ingredient also has an anticancer. This polychaete only appears once a year in May during the full moon, and at Indonesia only exists in two places, namely Maluku Sea and NTT Sea (East Nusa Tenggara).
Keynote Forum
Hendry Izaac Elim
Pattimura University, Indonesia
Keynote: Multitasking love herbal medicine and its impressive characters: A simple drug with seven healing system
Time : 12:10-12:45
Biography:
Hendry Izaac Elim, Ph.D., Lecturer & Young Scientist, now is an experience Indonesia scientist of nanoscience and nanotechnology (rank 23rd in 2017 based on Webometrics) and the 45th best Indonesia scientist according to SINTA-RistekDikti in May 2018), head of the Nanotechnology Research Center and Innovative Creation of the Pattimura University (UNPATTI), Chairman for Nanomaterials for Photonics Nanotechnology Laboratory (N4PN Lab), Physics Department, Faculty of Mathematics and Natural Sciences (FMIPA-UNPATTI), Ambon. Currently, he is building a Multidisciplinary Research Center of Excellence (MrCE) at UNPATTI. He already educated more than 50 graduated B.Sc. in physics from all simple advanced research on novel super fibers fabricated from all types of garbage materials, new liquid energy fuel cells system, and nanomedicine of herbal drugs, respectively. He is a member of top scientific society such as AAAS (ID No. 41737449) since 2017, and ACS (ID No. 31447106) in 2018. He was also awarded Saryalancana Karya Satya XX from President of Indonesia on 2nd May 2017 at Pattimura University
Abstract:
This simple breakthrough research output presents how a natural herbal drug called as Love herbal (LH) medicine works with seven healing systems as an integrated manner in the human body. By conducting a step by step investigation ranging from the pharmaceutical side, medical view of point, chemical characters, and multitasking physical system of nanomedicine, we summarize an incredible multitasking healing system with seven healing system of seven different decreases in just one LH medicine. The multiple works and interactions on how such marvelous herbal medicine carry out its healing organization are discussed based on an interdisciplinary study. We believe that such LH medicine will soon contribute to various societies in many different nations
- Nanomedicine and Nanobiotechnology | Applied Pharmaceutical science | Pharmaceutical Formulations | Design and Characterization of Nano Drug Systems | Computational Studies in Nanoparticles | Smart Drug Delivery Technology
Location: New York, USA
Chair
Oara Neumann
Rice University, USA
Co-Chair
Arend L Mapanawang
Stikes Halmahera, Indonesia
Session Introduction
Yucel Baspinar
Ege University, Turkey
Title: Ultrasound sensitive nanobubbles containing Paclitaxel, YM155, and siRNA as gene carriers for the therapy of lung cancer
Time : 13:45-14:10
Biography:
Yucel Baspinar studied Pharmacy at Free University Berlin, Germany and started as a research assistant at the same Institute in the Department of Pharmaceutical Biochemistry, Biopharmacy and Biotechnology with his Ph.D. thesis (2005-2009) entitled as “nano and microemulsions for the topical application of poorly soluble immune suppressive". After his Ph.D., he worked as Post-Doc for Prof. Burkhard Kleuser in the same Faculty, Department of Pharmacology and Toxicology in an EFRE (European Fund for Regional Development) project entitled with “Nanocarriersystems for dermatotherapy" (2009-2010). 2011-2013 he worked as Head of Drug Development and Quality Control Laboratory and in Biosimilar Laboratory in the Center for Drug Research & Development and Pharmacokinetic Applications at the Ege University in Izmir, Turkey. 2013- now he is Assistant Professor in the Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Ege University. The major research areas are Pharmaceutical Formulations of protein drugs and monoclonal antibodies prepared by the recombinant DNA technology and biosimilars
Abstract:
23% of the worldwide cancer-related death rate is due to lung cancer, more than the sum of breast, colon and prostate cancer. A great deal in common for almost each cancer type, including lung cancer, is an overexpression of the apoptosis inhibitor survivin. For improving the chemotherapy several strategies were performed. Previously, ultrasound sensitive nanobubbles containing paclitaxel, survivin-siRNA and survivin inhibitor sepantronium bromide (YM155), respectively, were developed against A549 lung cancer cells. The paclitaxel-loaded nanobubbles had a particle size of 309nm and a zeta potential of 34mV, the paclitaxel and YM155 loaded nanobubbles had a particle size of 57nm and a ZP of 47mV, while the PTX and siRNA loaded nanobubbles had a particle size of 252nm and a ZP of 27mV. The cytotoxicity studies revealed promising results and encouraged for further investigations. The aim of this study was to evaluate the siRNA complexation, serum stability, gene silencing efficiency, and Apoptosis. The developed nanobubbles were able to form a complex with survivin-siRNA and protected the siRNA from nucleases. The gene silencing efficiency and Apoptosis were evaluated, with and without ultrasound exposure, by qPCR and Apoptosis kits and showed that NB formulations were able to silence survivin expression and induce apoptosis in the A549 cell line.
Acknowledgement: This study has been financially supported by TUBITAK under grant code 116S213
Andrew J Kobets
Children's Hospital, USA
Title: Paramagnetic nanoparticles conjugated with lipopolysaccharide for blood-brain barrier disruption in a model of glioblastoma
Time : 14:10-14:35
Biography:
Abstract:
Background: Glioblastoma (GBM) is the most aggressive primary adult brain tumor with only 14.6 months of median survival. Carrier nanoparticles have emerged as a novel strategy for chemotherapeutic delivery, yet penetration of the blood-brain barrier (BBB) and tumor retention remain significant hurdles. The evolution of paramagnetic nanoparticles (PMNPs) shows promise for reliable, magnetically-targeted drug delivery, and coupled with a lipopolysaccharide-coating (LPS-PMNPs) allows for concurrent, reversible BBB disruption.
Jigisha P Badheka
PDU Medical College, India
Title: Smart drug delivery systems in anaesthesia an Indian scenario
Time : 14:35-15:00
Biography:
Jigisha P Badheka MD Anaesthesiology Working as an Associate Professor, In Department of Anaesthesiology, PDU Medical College, Rajkot Instructor for ACLS, BLS. PG Certificate course QM & AHO (Quality Management & accreditation of health Care organization) by AHA, and Disaster Management course by IGNOU. Wide experience in all the fields of anesthesia, Tutor for 11/2 yrs 1995-97 Class 1 anaesthesiology for 3 yrs.1997-99 Assistant professor for 7 yrs.1999- 2007 Associate professor since 2007 till date. Internal and external examiner since last 10yrs. Publications for national and international journals. Speaker for state and national conference.
Abstract:
The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. Novel Drug Delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. Whereas the Targeted drug delivery, sometimes called smart drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. It has advantages like the reduction in the frequency of the dosages, having a more uniform effect of the drug, reduction of the adverse effect of drugs and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult and the reduced ability to adjust the dosages. Newer intravenous drugs used for TIVA having a short duration of action so, fast recovery to maintain plasma level and to achieve the constant targeted level of sedation, analgesia, and anaesthesia targeted release system is useful which releases the drug in a dosage form. I will discuss a review of target controlled infusion total intravenous anaesthesia in India.
Selvie S Ticoalu, Mathen zebedeus
AKBID Makariwo, Indonesia
Title: The effect of granting Gedi leaf (Abelmoschus manihot L.) against blood sugar levels in pregnant women in North Halmahera
Time : 15:00-15:25
Biography:
Selvie S. Ticoalu is Gynecology specialists in Bandung, West Java at the Advent Bandung Hospital and teaches as lecturers AKBID Makariwo
Abstract:
Diabetes Mellitus is one of the causes of mortality and morbidity in all countries, where there are 3.5-4.3% of the world's population affected by diabetes mellitus. Based on data from the World Health Organization (WHO), the number of people with diabetes mellitus in the world reaches 285 million and is estimated to be more than 430 million by 2030. Type 2 diabetes mellitus (not insulin-related) is the most common, 95% of all cases of diabetes mellitus. The aim of the study was to determine the effect of giving Gedi leaf decoction (Abelmoschus manihot L.) to decrease blood sugar levels in pregnant women in northern Halmahera in 2018. The research method used was quasi-experimental with the design of one group pretest-posttest. The population in this study were 10 pregnant women at the Tiberias Tobelo clinic, with a sampling technique using a total sampling of 10 pregnant women with blood sugar. The results of the study showed that the average blood sugar levels in pregnant women before giving the decoction of Gedi leaves (Abelmoschus manihot L.) was 109.79mg/dL, and the average value of blood sugar in pregnant women after Gedi leaf decoction (Abelmoschus manihot L.) is 108.12mg/dL, the results of the analysis test with Paired sample T-Test obtained a significance value (p) of 0.002 significance value p<0.05. The conclusion that the average decrease in blood sugar levels in pregnant women is 1.67mg/dL, the statistical test results obtained that the effect of giving the leaves of Gedi leaves (Abelmoschus manihot L.) to pregnant women with blood sugar.
David Guerrero
Children's Hospital of Philadelphia, USA
Title: Nanocarrier with reversibly hydrophobized co-drugs for treating aggressive neuroblastoma
Time : 15:25-15:50
Biography:
David Guerrero in 2015, joined the research team of Dr. Michael Chorny at The Children’s Hospital of Philadelphia working on new drug delivery systems for treating arterial restenosis and cancer. Among other projects, he has worked on developing new strategies to target and treat aggressive pediatric solid tumors using polymeric nanoparticles formulated with novel mutual prodrugs (co-drugs). His research has contributed to a recent paper in Clin Cancer Res on enhanced intratumoral delivery of camptothecin-mitocan co-drugs for the treatment of high-risk neuroblastoma.
Abstract:
Nanomedicine-based delivery strategies have the potential to improve the therapeutic performance of a variety of anticancer agents. However, their clinical translation has been hampered by difficulty in achieving stable drug entrapment within nanocarriers, together with controlled release directly in the tumor tissue. In this study, we evaluated an experimental strategy that combines in situ activatable camptothecin-mitocan fusion molecules (co-drugs) and sub-100nm sized biodegradable nanoparticles (NP) derived using a nanoprecipitation-based formulation process. A series of reversibly hydrophobized co-drugs of a potent camptothecin agent, SN38, with tocol mitocans exhibiting a range of hydrolytic activation rates were encapsulated in 85±36nm sized NP with high efficiency (93±2% entrapment yield) using the optimized procedure. NP loaded with a phenolic ester co-drug were found to be most effective against both chemo-naïve and chemoresistant NB cells under conditions modeling different levels of exposure experienced by NB cells within the tumor. Phenolic carbonate and aliphatic ester designs were found to be notably less efficient. In an in-vivo model of previously untreated disease [IMR-32 orthotopic xenograft], nanocarriers with phenolic ester co-drug administered over 4 weeks [10mg/kg, twice a week] induced tumor regression and completely inhibited tumor growth over a 26-week period. The same co-drug/nanocarrier formulation tested against multidrug-resistant NB [BE(2)-C orthotopic xenograft] potently suppressed tumor growth and extended animal survival up to 7 weeks, in contrast to a marginal and transient effect of the clinically used SN-38 precursor, irinotecan [event-free survival of 3 weeks vs. 2 weeks in ‘no treatment’ and drug-free NP groups]. We conclude that camptothecin-mitocan co-drugs can be rationally designed as therapeutic cargoes for nanocarrier-based therapy of aggressive malignancies. The co-drug/nanocarrier combination strategy proven effective in preclinical testing experiments in this study holds promise as a treatment for high-risk NB and potentially can be extended to other pediatric and adult solid tumors
Fremiot J Mascarenhas
Bhavnagar Medical Association, India
Title: Transdermal drug delivery system
Time : 16:10-16:35
Biography:
Fremiot J.Mascarenhas, Qualifications: MBBS. From M. P. Shah Medical College, Jamnagar. Diploma in Anaesthesiology from M.P.Shah Medical College, Jamnagar. Currently practicing as a consultant Anaesthesiologist in city of Bhavnagar, Gujarat,India since last 25 years. The main field of interest are laparoscopy and Bariatric Anaesthesia and postoperative pain relief Post held: Secretary, Bhavnagar Anaesthesiologist' Association from 2011 to 2017. Presently Hon. Secretary, Bhavnagar Medical Association from 2015. Successfully Organized West Zone Anaesthesia Conference-ISACONGUJARAT2016 at Bhavnagar as Organizing Secretary
Abstract:
Transdermal drug delivery refers to a system in which a fixed amount of drug is delivered across the skin over a period of time to the bloodstream so as to maintain a therapeutic level of that drug. This method of drug delivery is painless and has excellent compliance in both pediatric and geriatric age group as it is pain-free and hassle free and does not need any specialized equipment for its use. Transdermal method of drug delivery has a great many advantages over other conventional routes of drug administration such as oral, intramuscular, intravenous. Medication applied in form of a fixed-dose adhesive patch that is applied to the skin surface and is absorbed through the pores of the skin and delivered in the bloodstream in a controlled way. The main objective of this painless route of administering a drug is to provide a therapeutic dose level of drug in the bloodstream with the minimal patient to patient variation while limiting the side effects if the same were to be administered by any other route.
Gershon Golomb
The Hebrew University of Jerusalem, Israel
Title: Monocyte-mediated delivery systems for theranostic applications in inflammatory-associated disorders
Time : 16:35-17:00
Biography:
Gershon Golomb is a Full Professor of Pharmaceutics at the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem. His works for many years has focused on drug delivery systems. His studies have developed controlled-release implantable and injectable drug/gene delivery systems; from hypothesis to in-vivo studies. He is an expert in targeted nanoparticles (polymeric-based and liposomes) for the treatment of cancer, cardiovascular disorders, and inflammatory-associated pathologies.
Abstract:
The mononuclear phagocytic system (MPS) is a part of the immune system that consists of phagocytic cells, primarily monocytes, and macrophages. Both circulating monocytes and neutrophils phagocyte debris, and foreign particles in the blood including particulate drug delivery systems. Inflammation characterizes several pathological disorders including cardiovascular disorders and cancer, and the inflammatory cascade involves significant infiltration of phagocytic cells. The propensity of monocytes for rapid phagocytosis of particulate matter provides a rational approach for delivering drugs in inflammatory-associated disorders. In this presentation, we will review therapeutic as well as diagnostic approaches mediated via specially designed nanoparticles (NPs), which are avidly internalized by circulating monocytes. Monocytes can serve as a courier of specific NPs to the CNS, bypassing the blood-brain barrier (BBB), effectively transporting drugs that are brain- impermeable. Liposomal delivery of quantum dots (QDs) enables an efficient fluorescent signal with no toxicity, in animal models of cardiovascular and cancer disorders. In addition, we will present recent results, unpublished, on the accumulation and retention of QDs in a mammary carcinoma model, following systemic administration, in comparison to passive delivery by the enhanced permeability and retention effect (EPR). The developed NPs delivery systems represent a novel approach for effective theranostic of inflammatory-associated disorders including cardiovascular, brain, and cancer diseases.
- Applied Pharmaceutical science | Pharmaceutical Formulations | Smart Drug Delivery Technology
Location: New York, USA
Chair
Vladimir P Torchilin
Northeastern University, USA
Co-Chair
Hendry Izaac Elim
Pattimura University, Indonesia
Session Introduction
Arend L Mapanawang
Stikes Halmahera, Indonesia
Title: Antioxidant activity and golobe level anticancer (Zingiberaceae) and leaves pangi
Time : 14:20-14:45
Biography:
Arend L Mapanawang has completed his Ph.D. from the Department of Pharmacy, College of Health Sciences, Yayasan Medika Mandiri Foundation, Halmahera, Indonesia. He is the Director of College of Health Sciences (STIKES Halmahera), Medika Mandiri Foundation, Halmahera, Indonesia. He is the Head of Internal Medicine Departement of Bethesda Hospital in Tobelo North Halmahera, North Moluccas.
Abstract:
Cancer is one of the diseases that the death rate is high because it has not found a drug that heals it completely. Researches continue to be developed incorrectly one is to develop a (Zingiberaceae) and leaf pangi (pangiense) vegetables consumed daily in Minahasa North Sulawesi by MTT and HPLC test methods golobe 6.5mg/ml and pangi 150mg/ml performed to see antioxidant activity and anticancer, can be seen the result that encourages use as protection or prevention is consumed as a health supplement either as an antioxidant or serves as a precaution against a variety of free radicals that have the potential to trigger the cells cancer in the body. FTIR test and spectrometer analysis and MTT Test, with the result of comparison of 1307- Fori 7/7 VS MCF-7 with IC50 (µg/ml) 1307,015 with positive control of cisplatin IC50 (µg/ml) 8,028. This shows golobe provides low activity but as supplements are very useful for protection or prevention. Likewise with a combination of pangi and golobe (dry simplicia) IC50 (µg/ml) 5860,470. This shows activity is weak but when given each IC50 golobe has more activity strong for cancer activity. At FTIR test leaf pangi has the highest peak 3510,6, intensity 16,36, base (H) 3747,85, base (L) 3497,09, area 141,06, Corona 113,25. Pangi leaves also have activity antioxidant and anticancer and has an antiretroviral activity that the herbs are from the grass become a new hope for prevention and even treatment in the future come.
Maykel A Kiling
Stikes Halmahera, Indonesia
Title: Identification of pentacosane compounds contained in the methanol golobe extract (Hornstedtia alliacea) in North Halmahera
Time : 14:45-15:10
Biography:
Maykel A. Kiling is Research lecturer and study program chairman at STIKES Halmahera
Abstract:
Golobe halmahera (Hornstedtia alliacea) is one type of farmer that has health benefits. The use of golobe halmahera is a source of energy when hunting, used when there are injuries and infections and this plant grows in the tropics including Halmahera. This research was conducted to identify chemical compounds contained in extra acids of methanol golobe (Hornstedtia alliacea). The design of this study was purely experimental conducted at the STIKES Halmahera pharmacy laboratory. The separation technique is maceration using methanol as a liquid dancer and the gas chromatography-mass spectrometry method is used to identify the compounds contained in the golobe halmahera methanol extract. The results showed that golobe halmahera contained alpha-cubebene 2.04%, myristaldehyde 1.33%, ethyl (9Z) -9-octadecenoate 2.13%, tricosane 3.78%, heptadecane 6.75%, pentacosane 28, 29%, heptafluorobutanoic acid, 3.15% heptadecyl ester, ethanol, 2- (octadecyloxy) 14.76%, all-trans-squalene 2.55%, 9-tricosane 6.10%, heptadecane10.05%, 17- hexadecyltetratriacotane 1.94%, (9Z) -9-tricosane 7.00%, benzenamine 2,3,4,5,6-penthacloro 7,96%.
Muhammad Jehangir
NovaMed Pharmaceuticals (Pvt) Ltd., Pakistan
Title: Pharmaceutical impurity analysis of raw materials and final product by using analytical techniques
Time : 15:10-15:30
Biography:
Muhammad Jehangir has 13 years diversified experience of Quality Control, Quality Assurance, Registration Affairs, Product development and Pharmaceutical manufacturing, Process Planning, Method development, Method validation, Statistical Methodology, Process & Cleaning Validation, Equipment Validation etc. Certificate Courses on cGMP, cGLP, Process Validation, CTD Documents, ISO 9001:2008, 13485-2003,14001-2004 have strong scientific, analytical, statistical, managerial and training skills. Currently, he is working as a Senior Manager Quality Control and validation for Novamed Pharmaceuticals. It is toll manufacturing-oriented company, manufacturing of companies like Getz Pharma, ICI, SEARLE, Macter, Ray, and for Sanofi-Aventis. He is also looking after the Quality of Novamed Healthcare, the nutraceutical and cosmeceutical manufacturing plant.
Abstract:
The evaluation of pharmaceutical raw materials and finished products for impurities and degradation products is an essential part of the drug development and manufacturing testing process. Additionally, toxicological information must be obtained on any drug-related impurity that is present at a concentration of greater than 0.1% of that of the active pharmaceutical ingredient (API). In pharmaceutical QC and manufacturing, impurity analysis has traditionally been performed by HPLC with UV, PDA, or MS detection. As it is essential to detect and measure all of the impurities in the sample, it is necessary to have a high-resolution separation process. This usually involves long analysis times resulting in low throughput. As candidate pharmaceutical compounds become more potent and are dosed at lower and lower levels, ever more sensitive assays are needed to detect and measure impurities. The low throughput of HPLC can become the rate-limiting step in product release testing or process evaluation. Since much of the process of impurity identification involves the coupling of LC to sophisticated MS, any reduction in analysis time will result in more efficient use of these significant investments. Analytical technology advances such as UPLC and UPC offer significant improvements in throughput and sensitivity, with benefits to the process of product release and identification of drug-related impurities. The most characteristic feature of the development in the methodology of pharmaceutical and biomedical analysis during the past 25 years is that HPLC became undoubtedly the most important analytical method for identification and quantification of drugs, either in their active pharmaceutical ingredient or in their formulations during the process of their discovery, development, and manufacturing.
Muhammad Shahid Khan
NovaMed Pharmaceuticals (Pvt) Ltd., Pakistan
Title: Formulation development and in-vitro characterization of orodispersible tablets of Piroxicam and Lidocaine HCl for use in dental pain
Time : 15:30-15:50
Biography:
Muhammad Shahid Khan has got more than 18 years of experience in the pharmaceutical industry in different posts. He is currently working as Plant Manager in NovaMed Pharmaceuticals (Pvt) Ltd., a local firm but also manufacturing products for many multinational companies like Sanofi Aventis, ICI, Getz Pharma, and Searle. He is overall responsible for the whole plant. He has attended many training workshops, exhibitions and technical seminars in Pakistan and abroad. He has got training from France. He has visited many countries of the world for training and to attend exhibitions.
Abstract:
The purpose of this research study was formulation development and in-vitro characterization of orodispersible tablets of Piroxicam and Lidocaine HCl along with the development and validation of the novel method of simultaneous estimation of both the drugs on HPLC. The aim was to develop a product that will provide immediate relief from the pain of dental origin, due to the local action of lidocaine in the mouth and also produce long-lasting analgesia by piroxicam after absorption. Orodispersible tablets of Piroxicam and Lidocaine HCl were developed by direct compression method. FTIR spectroscopy was used to study drug-drug and drugs-excipients compatibility. The FTIR spectra showed that there was no interaction between the two drugs and also between the drugs and excipients which proved that all the ingredients are compatible. The assay method for simultaneous estimation of both the drugs on HPLC was developed successfully. The developed method was also validated by following ICH guidelines.